Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

X
Trial Profile

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gilteritinib (Primary) ; Cefalexin; Fluconazole; Midazolam; Posaconazole; Voriconazole
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CHRYSALIS
  • Sponsors Astellas Pharma; Astellas Pharma Global Development
  • Most Recent Events

    • 17 Jun 2021 Results of retrospective analysis assessing whether prior TKI therapy affected response and survival in (phase 1/2 CHRYSALIS (n=145) and phase 3 ADMIRAL (n=371)) these two trials, presented at the 26th Congress of the European Haematology Association.
    • 07 Jun 2021 According to an Astellas Pharma media release, results of retrospective analysis assessing clinical outcomes from CHRYSALIS and ADMIRAL studies were presented at he European Hematology Association (EHA) virtual congress 2021.
    • 08 Dec 2020 Results of retrospective analysis assessing clinical outcomes from CHRYSALIS and ADMIRAL sudies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top